• Home
  • Study Details

Pivotal study to assess the efficacy, safety and tolerability of dupilumab in patients with moderate-to- severe COPD with Type 2 inflammation (BOREAS)

The goal of this study is to evaluate an investigational medication and its effect on lung function and symptom control. Participants will either be given either the active medication or a placebo (inactive solution that does not contain medication) as an injection given every two weeks in clinic for one year.

Age & Gender

  • 40 years ~ 80 years
  • Male, Female


North Carolina (Statewide)


up to $2,260

In-person visits : 31
Total length of participation : 76 weeks

Looking for Specific Volunteers

Able to participate:

  • Have a diagnosis of COPD, emphysema, or chronic bronchitis
  • Currently on daily inhalers
  • History of two or more flares of COPD

Not eligible if:

  • Females who are currently pregnant or breastfeeding
  • Oxygen use for more than 12 hours a day
  • Evidence of Right Heart Failure

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Brad Drummond

Study Topics

Lungs and Breathing
Substance Use (tobacco, alcohol, opioids, etc)

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.